Longeveron rises as it wins China patent for stem cell test

Longeveron LGVN.O shares rise 6% to $1.23 premarket

Biotech firm says secured a patent in China covering tests that measure the strength and quality of its stem cell products, expanding its global patent protection

The patent, valid through 2041, covers potency tests for mesenchymal stem cells, which are adult stem cells used to help repair tissue and reduce inflammation - LGVN

Adds that the tests apply to stem cells derived from bone marrow, fat, blood, organs and lab-made stem cells, helping ensure safety and effectiveness of therapies

Says the patent adds to its international portfolio of 52 patents

Longeveron’s lead experimental therapy is being tested in Alzheimer’s disease, rare pediatric heart disease and age-related frailty

As of last close, stock has nearly doubled YTD